For other salt forms please inquire. According to Schwede et al. (2015), Sp-8-BnT-2'-O-Me-cAMPS is the most potent 2'-substituted activator of Epac2 that efficiently discriminates against Epac1 in vitro (AC50 Epac2 = 1.5 μM (1.8 µM for cAMP) and rel. kmax = 4.3 (1 for cAMP)). Due to the 2'-substitution it is an extremely poor PKA activator and thus allows for specific activation of Epac2 over PKA. In human osteosarcoma U2OS cell lines stably expressing Epac1 or Epac2, Sp-8-BnT-2'-O-Me-cAMPS does not induce Epac signalling at 100 µM, which may be due to inefficient cellular uptake in this biosystem. Detailed technical information available. Reference: Schwede et al., PLoS Biol., 13(1): e1002038 (2015) (Link to PLoS Biology).
Related products: Biolog also offers Sp-8-BnT-cAMPS (Cat. No. B 046 / "S-220") which has increased in vitro and in vivo potency compared to Sp-8-BnT-2'-O-Me-cAMPS, but slight potency to activate PKA, as well as the well-established Epac agonist 8-pCPT-2'-O-Me-cAMP (Cat. No. C 041) which selectively activates Epac1 over Epac2 (Schwede et al. 2015).
|Cat. No.||B 056|
|Patent Information||The reagent is protected under patent EP 1511757 and foreign equivalents issued or licensed to BIOLOG Life Science Institute.|
|Purity||> 98% HPLC|
|Storage temperature||-20°C / -4°F|
|Molecular formula||C₁₈H₁₉N₅O₅PS₂ · Na|
|Molecular weight [g/mol]||503.5|
|cAMP modified at the exocyclic oxygen||axial (Sp-)|
|Absorption max [nm]||283|
|Molar extinction coefficient ε [L·mol⁻¹·cm⁻¹]||17100|